Elinafide

Drug Profile

Elinafide

Alternative Names: LU 79553

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Amides; Isoquinolines
  • Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
  • 14 Oct 1998 A phase I study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top